On September 29, 2025, Dogwood Therapeutics, Inc. (NASDAQ:DWTX) announced a royalty-free, global license deal with Serpin Pharma for SP16 for the management of cancer related pain (CRP), including a ...
ATLANTA, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a clinical-stage biotechnology company developing new medicines to treat pain and ...
ATLANTA - Dogwood Therapeutics, Inc. (NASDAQ:DWTX), a clinical-stage biotech company with a market capitalization of $10.55 million, has secured a royalty-free global license for Serpin Pharma’s SP16, ...
All-Stock Licensing Deal for Treatment of Cancer Related Pain On September 29, 2025, Dogwood Therapeutics, Inc. (NASDAQ:DWTX) announced a royalty-free, global license deal with Serpin Pharma for SP16 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback